GHP Q3 2021

Q3 2021 ghpglobal health & pharma Emerald - The future of fat loss technologies Medical lasers have become a standard part of many surgeon’s toolkits, allowing them to perform incredibly precise operations focused on specific areas of the body. The development of these lasers has been a key to the success of the industry, and one of the leading developers is the teamat Erchonia Lasers Ltd who specialise inNon-thermal Low Level Laser technology. Worthy winners in the GHP Global Excellence Awards, where they earned 2021’s Award for Excellence in Innovation, we thought it time to examine what sets the teamapart from the competition.

ghpglobal health & pharma Personalizing Decision-Making for Breast Cancer Treatment DCISionRT is the culmination of ground-breaking technology created by PreludeDx, the California-based breast cancer diagnostics company dedicated to improving treatment and care for patients. Using advanced artificial intelligence andmachine learning, DCISionRT provides personalized results that influence physician decisions regarding the best treatment pathway for individual patients diagnosed with ductal carcinoma in situ (DCIS), also known as Stage 0 breast cancer, enablingmore effective care and alleviating guesswork on healthcare providers when rendering treatment recommendations. Find out more about the science behind DCISionRT and the team leading a revolution in cancer treatment. Q3 2021 Best DCIS Testing Solution 2021: DCISionRT®

GHP / Q3 2021 3 Contents , Welcome to the 2021 Q3 edition of Global Health & Pharma Magazine, providing you with all the latest news and features from across the healthcare and pharmaceutical landscape. As we come towards the final quarter of a second year shaped by a global pandemic, we might be excused for thinking only on the exceptional work around Covid-19 when reflecting on the successes achieved by the healthcare and pharmaceutical industries this year. However, over the last quarter, the global companies within these vital sectors have remained just as – if not more – busy with endeavours outside the pandemic as well. From the ground-breaking personalisation technology within breast cancer treatment being developed by DCISionRT, to VativoRx’s commitment to raising the standards in Pharmacy Benefit Management, to the many other stories of exceptional and transformational work exhibited in this issue of GHP Magazine, it is clear that the global health and pharmaceutical industry has a lot to be proud of this quarter. Thus, we invite you to dive in and discover more about these fantastic companies and their life-changing work – whether it be in aesthetic treatments or surgical procedures, pharmaceutical innovations or enhanced services. We hope you enjoy this issue of GHP Magazine and wish you safe and well until we meet again in the Q4 edition. Alex Abraham, Editor Website: AI Global Media, Ltd. (AI) takes reasonable measures to ensure the quality of the information on this web site. However, AI will not assume any legal liability or responsibility for the accuracy, correctness or completeness of any information that is available through this web site. If errors are brought to our attention, we will try to correct them. The information available through the website and our partner publications is for your general information and use and is not intended to address any particular finance or investment requirements. In particular, the information does not constitute any form of advice or recommendation by us or any of our partner publications and is not intended to be relied upon by users in making or refraining from making any investment or financial decisions. Appropriate independent advice should be obtained before making any such decision. Any arrangement made between you and any third party named in the site is at your sole risk and responsibility.

4 GHP / Q3 2021 Contents , 5. News 6. Emerald - The future of fat loss technologies 10. Personalizing Decision-Making for Breast Cancer Treatment 14. The Bright Lights of Aesthetic Excellence 15. PBMs Can Do Better 16. Crawley Chiropractic Centre: Chiropractic Clinic of the Year 2021 - Sussex 17. Care That is Truly Unrivalled 18. The New Non-Surgical Aesthetic Treatment from Nina Bal 19. Comprehensive Compliance Solutions for Medical Technology 20. The Secret to Looking Youthful 22. The Support System Behind the USA’s Medical Technology Boom 23. Award Winning Mobility Solutions from Rehasense 24. The ‘WOW’ Factor 25. Health and Wellness Excellence 26. A New Line of Products for the UK’s Cosmetic Professionals 27. Expert Work, Professionally Augmented 28. Bespoke, Flexible Solutions 30. Unravelling Complexity 31. Relaxed, Pain-Free Dentistry 32. Restructure, Reorganise, Refocus 33. Quest for Excellence 34. Elevating Excellence in Private Healthcare Transport 36. Bringing International Pedigree to Local Sports Training 37. Medical Devices and the Future of Healthcare 38. Special Delivery for the Healthcare Sector 39. Faster, Better, Customer-Centric Insurance Solutions 40. Care for Women 41. Global Veterinary Opportunities 42. A Clean Getaway 43. Beauty, Art, Science 44. The New Rival to the Skin Clinics of Harley Street 46. Efficient CDMO Services 47. Protecting the “Things” that Protect Human Lives 48. Creating Value Through Collaboration 49. Not an Agency, but a Partner 50. Pioneering Varicose Vein Treatments 51. Intelligence, Quality, Empathy 52. The Company Ensuring Oversight in Medical Device Trials 54. Treatment Where Patients Need it Most 55. African Wellness Products with Global Prestige 56. Exemplary Periodontal Treatments 57. Helping Spinal Surgeons Help People 58. Expert Contamination Monitoring Solutions 59. Winners’ Listings Contents

GHP / Q3 2021 5 NEWS The aftermath of Long Covid, and the full impact on employers, will only become fully apparent when employees return to the workplace, says RedArc Nurses. Long Covid aftermath will be more evident when employees return to work, says RedArc Christine Husbands, managing director for RedArc says: “While we’ve been living with the pandemic for a long time now, the situation regarding Long Covid is complex and still emerging. It’s likely that some employers will not really know how badly their staff have been affected until they start to return to the office.” Employees who are feeling the most severe effects of Long Covid may be well-known to employers, however, employees who are only starting to realise the effects of Long Covid may have been battling through symptoms - such as fatigue - without alerting their employer. Once they start returning to the workplace - with the associated commute and more stressful daily environment – this may unravel the wellbeing of these employees and put additional pressures on both them and businesses. Christine Husbands continued: “A complication of Long Covid is that it’s not a static condition – symptoms such as joint pain, headaches, fatigue, digestive issues, and vertigo can improve and relapse causing some employees to feel that they are unable to cope.” Support for a changing condition Relying on generalised advice isn’t enough for Long Covid: everyone is different, so it’s vital that support is personalised: it’s important to get to know the person, their symptoms, their working environment and their capacity to work. Support needs to include help for specific symptoms – both physical and mental - but also advice on pacing and rehabilitation, as well as on returning to the workplace. Employees benefit from advice in navigating wider support from their GP, the NHS, Long Covid clinics, local support groups, specialist therapies, second medical opinions as well as additional support within employee benefits. Husbands continued, ‘By helping employees through Long Covid, employers are actually helping themselves in returning their workforce to full strength and capacity as much as is possible – and this is going to be a vital aspect of living with Covid-19.” Huadong Medicine and PulseCath Announce Strategic Collaboration to Develop and Commercialize the iVAC mechanical circulatory product in Greater China PulseCath B.V., a leader in the expanding field of percutaneous ventricular assist devices for high-risk PCI, and Huadong Medicine Co., Ltd., today announced that the companies have entered into an exclusive collaboration to develop and commercialize the iVAC technology in mainland China, Hong Kong, Macau and Taiwan (Greater China) and selected other Asian Pacific countries. The collaboration agreement between PulseCath and Huadong provides Huadong Medicine with a license to distribute iVAC technology in mainland China, Hong Kong, Macau and Taiwan (Greater China) and selected other Asian Pacific countries as well as for local manufacturing and development. PulseCath will retain all rights in the rest of the world. "With extensive regional experience, the right development and regulatory capabilities, and access to a deep local network of hospitals and clinics across Greater China, Huadong Medicine is an ideal partner for us," said Oren Malchin, PulseCath's Vice President for Marketing and Sales. "This collaboration reflects iVAC pulsatile technology's potential to deliver meaningful value to high-risk PCI patients as well as our ability to translate our work in cardiac assist devices into long-term relationships that create sustainable value for PulseCath and our partners. We look forward to working closely with Huadong Medicine to develop and commercialize the iVAC technology in Greater China as we continue to advance the iVAC product family, develop new products, conduct further clinical studies and support our application for FDA approval, which we expect for 2022 in the United States. Under the terms of the agreement, PulseCath will receive a significant investment in the company's share capital and is eligible to receive a further investment as a result of potential development and regulatory milestones. In addition, PulseCath will receive a payment for regulatory activities and production in China dedicated to Greater China and selected other Asian Pacific countries. PulseCath is also eligible to royalties on iVAC's commercial sales by Huadong Medicine in their commercial region. Huadong Medicine will be responsible for the development as well as regulatory submissions and commercialization of iVAC in Greater China and selected other Asian Pacific countries. Huadong Medicine will also have the opportunity to participate in global clinical studies of PulseCath conducted by PulseCath. PulseCath will continue to be responsible for the development and commercialization of iVAC in Europe, the United States, and other geographies. Partnership accelerates the development of the iVAC 2L mechanical circulatory device in Greater China. Expands Huadong Medicine's medical portfolio for cases of high-risk PCI with innovative percutaneous ventricle assist devices based on innovative pulsatile technology. PulseCath will receive a significant investment in its share capital and in payments for regulatory and development activities and is eligible to royalties on iVAC's commercial sales by Huadong Medicine in their commercial region.

6 GHP / Q3 2021 , Apr21272 Medical lasers have become a standard part of many surgeon’s toolkits, allowing them to perform incredibly precise operations focused on specific areas of the body. The development of these lasers has been a key to the success of the industry, and one of the leading developers is the teamat Erchonia Lasers Ltd who specialise inNon-thermal Low Level Laser technology. Worthy winners in the GHP Global Excellence Awards, where they earned 2021’s Award for Excellence in Innovation, we thought it time to examine what sets the teamapart from the competition. Emerald - The future of fat loss technologies In 1996, Mr Steve Shanks and Mr Kevin Tucek founded Erchonia Corp. Their aim was simple – to develop and manufacture Non-thermal Low Level Lasers. Through an approach which has embraced the potential of innovations within this technological area, the team have been able to achieve incredible success in North America, and are rapidly expanding around the world. Their work has had an astonishing impact on the way in which medical treatments are handled. Of course, trading around the world is no easy matter. Erchonia Corp is based in the US, and required a different base of operations to reach markets in Europe, the Middle East and Africa (EMEA). The UK was ideally placed for such a venture, and Erchonia Lasers Ltd was the result. Working closely with their US counterparts, the EMEA team work tirelessly to give their customers the best possible products, service, training and support when it comes to non-thermal laser technology, also educating on the different delivery mechanisms associated with Low Level Laser. The team’s work covers an enormous range of different areas, with the lasers specifically designed to act as an advanced delivery system transporting photonic energy via electromagnetic energy transfer into the body through a ‘true’ laser beam. This impressive, clinically proven technology, can be used to treat a wide variety of conditions including the reduction of body fat, adjusting the appearance of cellulite, eliminating pain, accelerating healing, treating acne and treating foot fungus to name but a few. Such amazing range of ability is a boost to the medical industry, ensuring that their newest purchase is far more than just a one-trick-pony enabling diversification as well as increased efficacy. At the heart of Erchonia is a determination to meet the desires and needs of clinicians and patients. The potential of non-thermal laser which falls under the umbrella of lowlevel laser therapy could easily transform the way in which people are treated. As such, the team make every effort to ensure that the service that they offer is one which is worldclass. The success of their efforts can be seen easily in the range of different services that are used, with new and exciting solutions designed for surgeons, aesthetic doctors, chiropractors, physical therapists, general pain management clinics and veterinarians worldwide. Reaching such a broad audience has been one of the keys behind Erchonia’s success. The use of laser therapy has a long and happy history within the healthcare industry, traditionally being used to pierce through skin in order to cauterise a wound. Harnessing the properties of this non-thermal laser technology by electromagnetic energy transfer allows clinics and their patients across the board to access the

GHP / Q3 2021 7 Emerald - The future of fat loss technologies enormous potential they possess in increased efficacy, especially compared to standard therapies, without the resultant pain and tissue damage, or downtime. The Erchonia team achieve this exceptional addition to a clinician’s options through careful and thorough investigation via Level One (510k) placebo controlled, double blind, randomised, multicentre clinical trials (using LED in the placebo effect) allowing them to achieve 18 of the 21 US FDA market clearances given to Low Level Lasers. They aren’t just designed to be magnificent examples of engineering, but practical additions to a clinic. Hot lasers carry with them a number of drawbacks, namely the challenges involved in purchasing and maintaining them, as well as the difficulties of patient recovery. A nonthermal laser device is a less expensive treatment overall, while diminishing the safety concerns that are ever present with laser use. ‘True’ non-thermal

8 GHP / Q3 2021 , laser light is coherent, collimated, monochromatic ,visible light, unlike other technologies that fall within this category, allowing Erchonia lasers to optimise the dose of photonic energy delivered to the mitochondria of the cell. The result is a clinic that is transformed into something highly efficient and incredibly advantageous to their patients. Throughout every level of the firm’s operation, quality has remained first and foremost, and there are no shortcuts taken or compromises made. The desire to find new ways of using nonthermal lasers has been a huge part of the team’s success, and this exploratory method is only possible if every step is made towards ultimate quality and patient satisfaction. Despite the global nature of Erchonia, what unites every aspect is the pride contained within every product. The high quality of workmanship from the humblest fitting to the most sophisticated engineering is clear for all to see. The comprehensive approach is made possible through a process that sees each product completed ‘in-house’. The team are over 85% self-reliant in all facets of the company. All products that bear the Erchonia name undergo the same impressive manufacturing and assembly processes, combined with oversight that ensures no part goes awry. With demand being international, these products are produced to FDA, ISO, OSHA and MDSAP standards. The commitment to quality in all areas is the key behind the impressive reputation that Erchonia have been able to garner for themselves. When medical professionals need a product that can stand the test of time, they more often than not turn to Erchonia to see what they can offer. While the team’s products blow the competition away, it’s in the area of research and development that the team thrive most clearly. Erchonia Corporation has a strong history of innovation, for which it has achieved success in GHP, but this has only been possible thanks to an astonishing amount of investment. The team have over $5 million invested in research and development at any one time to make sure they keep pushing the boundaries and defying the dogma. These studies have an impact not just on the company, but on the scientific community as a whole. Through this commitment to higher standards and the exploration of new boundaries, the team at Erchonia has been able to push the limits of the market for the benefit of their clients. Innovation is one of the key tenets of Erchonia, with every aspect of the business built around ensuring that the team can continue to grow in their ways of working. Leadership comes from a cross-functional and diverse senior management team, comprised of business, sales, marketing, compliance, research, and engineering expertise. By combining all of these aspects, the team can enact a full spectrum view of proceedings that can benefit the whole company, as opposed to specific areas. This approach, which embraces novelty and original thinking, is what has seen the company grow over the last two decades. It makes it possible for the leadership to explore a problem or possibility from all sides, in its true height, depth and breadth. It’s little wonder that such strong consideration for the needs of clients has allowed the team to achieve such an incredible degree of success over the years. Those clinics which have taken up the use of an Erchonia laser have found it quickly becoming an indispensable tool in many unique situations, but one of the most rewarding for the Erchonia team is that of pain management and accelerated healing. Chronic pain can be incredibly challenging to treat, but the use of specific treatments such as laser therapies have been known to bring about fast and effective relief. The specifics of this field are not yet fully understood, with scientists still exploring the impact and potential effects of this new area of laser therapy, but it holds within it enormous potential. The use of non-thermal lasers could transform the lives of those with Chronic pain. The lasers can penetrate the skin, as well as soft or hard tissues, and are able to make an enormous difference to a person’s wellbeing with no visible impact. Often, the use of an Erchonia laser can have an immensely positive effect on inflammation, pain and healing. Cells absorb the light energy from the laser and are able to convert it into cell energy, which suppresses pain and reduces

GHP / Q3 2021 9 Emerald - The future of fat loss technologies the inflammatory pathways. The results speak for themselves, with short, regular treatments offering patients much needed reprieve from pain over the longer term. The use of laser treatments can take the strain from other options which some would consider riskier. Naturally, most medical professions try to avoid the use of surgical options if at all possible. While the use of various medications seemed the natural solution to this, they bring their own problems. Medicines like acetaminophen or non-steroidal anti-inflammatories often bring their own unique and undesirable side effects at best or do little to help at worst. The use of opioids has its own risks, this time by way of misuse and abuse by the patient. As non-thermal laser treatment has no recovery time or reported side effects, while being painless and safe to use, it has become the recommended choice for many. The most exciting aspect, however, is the way in which companies like Erchonia have been able to open the market up so that clinics can use this treatment easily and effectively. Historically, it was incredibly difficult to access such resources, but now many clinics have them as standard to work alongside their own skillset. That is the result of what Erchonia have done, both in North America, Europe and beyond. It’s clear that the medical industry is one which is constantly innovating, but one of the biggest innovations is the work that has been championed by the team at Erchonia. Their high-quality products have opened the door to new treatments that have transformed the industry at large. It’s an incredible achievement! Thanks to this organisation, more patients can access better healthcare that relieves their pain quickly and effectively, and also reduce their body fat whilst preserving the endocrine function of the cell which can be discussed in more depth at a later date. Innovation is at the centre of what Erchonia do! Name: Kate Murray Email: [email protected]

10 GHP / Q3 2021 , Feb21449 DCISionRT is the culmination of ground-breaking technology created by PreludeDx, the California-based breast cancer diagnostics company dedicated to improving treatment and care for patients. Using advanced artificial intelligence andmachine learning, DCISionRT provides personalized results that influence physician decisions regarding the best treatment pathway for individual patients diagnosed with ductal carcinoma in situ (DCIS), also known as Stage 0 breast cancer, enablingmore effective care and alleviating guesswork on healthcare providers when rendering treatment recommendations. Find out more about the science behind DCISionRT and the team leading a revolution in cancer treatment. Personalizing Decision-Making for Breast Cancer Treatment Founded in 2006, PreludeDx is a leading personalized breast cancer diagnostics company in the US. The company’s mission is to provide physicians with the tools for better decision-making concerning patient treatment and care. Old testing methods that use clinical and pathological factors are getting an upgrade, now incorporating genomic testing through advanced AI technology that enables accuracy and personalization. In doing so, PreludeDx aims to improve the outcomes of patients afflicted with breast cancer, while simultaneously alleviating financial burdens and pressures on resources within healthcare systems. The Science Behind the Innovation Using technology licensed from the University of California, San Francisco, PreludeDx created actionable, evidence-based tools in the form of a patented molecular test. DCISionRT is currently the only DCIS (ductal carcinoma in situ) test designed to predict radiation therapy benefit. The test combines cutting-edge innovation in molecular biology with AI and machine learning to analyze the tumors of women diagnosed with DCIS breast cancer. Relying on a comprehensive assessment of the proven disease progression pathways along with standard clinical factors, the test is able to predict the individualized likelihood of these women developing a DCIS recurrence and/or invasive breast cancer within ten years, with and without adjuvant radiation therapy after Breast Conserving Surgery (BCS). DCIS is currently the most commonly diagnosed form of non-invasive breast cancer, affecting more than 60,000 women in the US alone each year. And while there are a variety of treatment patterns available for DCIS that utilize clinicopathological features and nomograms, none share the same personalization and quantification of risk and radiation therapy benefit as DCISionRT. This defaults to a one-size-fitsall approach in which many patients receive radiation therapy regardless of their unique level of risk, creating a prevalence of both over- and under-treatment. The research to create DCISionRT was built on funding from the National Cancer Institute in an effort to better understand the biology of DCIS. In the largest combined study population ever carried out in the development Best DCIS Testing Solution 2021: DCISionRT®

GHP / Q3 2021 11 Personalizing Decision-Making for Breast Cancer Treatment

12 GHP / Q3 2021 , of a DCIS test, PreludeDx used the findings from multiple studies totaling nearly 3,000 women to create the non-linear risk algorithm that exists at the heart of DCISionRT test results. Suitable for testing on both presurgical biopsies and surgical specimens, the combination of the data acquired for the nonlinear algorithm with DCISionRT’s sophisticated AI and machine learning capabilities are well suited for intricate biological disease processes – far more so than traditional linear algorithms. DCISionRT is the only test of its kind to be validated with Level 1B Clinical Evidence, which verifies consistent results across multiple studies, including a randomized clinical trial. The studies were carried out in medical and research centers and hospitals across the globe, with the SweDCIS randomized clinical trial in Sweden taking on landmark independent clinical validation of DCISionRT. The trial found that patients with low Decision Scores received no significant invasive risk reduction from radiation therapy after surgery, whereas patients with elevated Decision Scores showed a 9% reduction in invasive risk. The study concluded that DCISionRT—for the first time in the history of DCIS treatment— enables physicians to predict the extent to which patients would benefit from radiation therapy. The effects of these findings were substantial, not just for the relief of pressure on patients and healthcare providers, but in the short-term too. The results of the DCISionRT studies allowed for triage and prioritization of patients for surgery based on actual biological urgency at the height of the COVID-19 pandemic. Second Opinion from Expert Breast Pathologist As a hub of expertise for breast cancer treatment and care, PreludeDx also offers its knowledge base and resources to patients via Breast SOS™, a second opinion service to help patients better understand their diagnosis through expert verification and—if required— amendment. The specialized clinic, led by world renowned breast pathologist, David J. Dabbs, MD, is designed to offer patients secondary insight from the third-party perspective of a healthcare professional. A second opinion is recommended for a myriad of reasons, including uncertain or unusual circumstances surrounding a diagnosis, the patient having concerns or questions, a health insurance plan requiring it before approving a particular treatment, or for planning further treatment after surgery. Unfortunately, only 10-20% of patients have access to qualified individuals with the nuanced and specialist training in breast pathology required to make an informed and comprehensive recommendation. Every patient should have the right and the ability to access a second opinion. Without it, onesided diagnoses risk inaccuracies that can lead to unnecessary clinical interventions, extraneous costs, and increased anxiety for patients and their families. Breast SOS grants patients confidence in their diagnosis and offers them all the information they will need to know in accessible literature and engaging discussion, acting as a trusted partner and source of support throughout the process. The People Behind the Innovation Patients and physician clients are able to trust in PreludeDx and have confidence in its team. The CLIA (Clinical Laboratory Improvement Amendments) covers approximately 260,000 laboratory entities and falls under regulation by the Centers for Medicare and Medicaid Services (CMS) for all laboratory testing performed on humans in the US. The Division of Clinical Laboratory Improvement & Quality—within the Quality, Safety & Oversight Group, under the Center for Clinical Standards and Quality (CCSQ)—has the responsibility for implementing the CLIA Program. CMS has granted the College of American Pathologists (CAP) Laboratory Accreditation Program deeming authority, which has enabled CAP inspection in lieu of CMS inspection. CAP has retained its deemed status with the Joint Commission, the United Network for Organ Sharing, the National Marrow Donor Program, the Foundation for the Accreditation of Cellular Therapies, among many US state agencies. PreludeDx’s team of highly-trained quality and compliance staff play an integral role in maintaining the standards of operations, staying abreast of the ever-evolving laws and regulations. Driving Innovation is, after all, one of the core values upon which PreludeDx was built, alongside Quality First, which guarantees the prioritization of quality systems, processes, and results, and Patient Focused, recognizing that behind each sample is a patient who deserves respect and conscientious treatment. PreludeDx exists to serve the needs of its patients, and as such, is committed to handling each sample with care and providing

GHP / Q3 2021 13 Personalizing Decision-Making for Breast Cancer Treatment results to the patient and physician in a timely manner. With these values at its center, PreludeDx has built a company culture that takes pride in the lifechanging work it accomplishes as a unified team. This sense of camaraderie and pride is embedded into the PreludeDx modes of business and flows throughout the company, from the senior management team to new recruits welcomed into the company. The strong reputation that PreludeDx has built in its market has attracted some of the top talent in the industry to join its team and contribute to the innovation and progression of the firm’s scientific research and development. Moreover, with an open-door policy throughout the leadership, senior management, and HR teams, every team member—whether new or long established—is able to benefit from a supportive working environment that provides the launchpad for excellence. A Future of Innovation Now, with its established presence at the forefront of its industry, PreludeDx is looking to continue its evolution, beginning with the continued expansion of physician adoption of DCISionRT across the US. PreludeDx has now entered the international markets, introducing physicians across the globe to its gamechanging technology and helping patients with DCIS worldwide to attain more accurate and effective treatments. PreludeDx intends to move beyond DCIS to implement its research in the development of expanded genomic solutions for early-stage breast cancers. This advancement would be instrumental in helping even more patients gain access to the most accurate diagnoses and treatments available. PreludeDx will continue to strive for greater innovation through advanced technology and profound research, in order to improve and ultimately save lives around the world. Company: PreludeDx Web Address:

14 GHP / Q3 2021 , Neo Elegance’s light-based aesthetic treatments have secured it significant goodwill within its market segment, being pioneers of the LEDmask treatment in the UK that propelled them into the spotlight. Nowadays, it is more determined than ever to continue striving for better andmore effective treatments, something that has earned it ‘2021’s Award for Excellence in LED Light Therapy Services’ for its ingenuity and tenacity. Neo Elegance is the company behind exemplary, innovative aesthetic devices that are both for at-home use and for use by professionals. By serving both of these target markets, it has truly made its name in the niche of aesthetic technological devices, providing non-invasive skincare methods that use LED light treatment as a basis, something that has been making waves in the industry. Fundamentally, this awardwinning brand is trusted by the best in the business from high-ranking professionals to celebrities like Jessie J. Neo Elegance has been showcased in the Sun, Glamour, ITV Be, Mail Online, and more. The Illumination LED Face Mask was one of the first LED powered masks to be brought to the UK, and immediately started earning Neo Elegance notoriety in the process. There are three treatments modes available through this product; the antiaging treatment that uses red and near infrared LED light, the anti-blemish function that uses blue and near infrared LED, and the total rejuvenation function that uses red, blue, and near infrared. The work of this mask is clear after the first use, improving the appearance of fine lines and wrinkles, as well as improving the skin tone, texture, and firmness of the skin, reducing breakouts and helping skin that is prone to blemishes. But what’s new? Well, recently, the exemplary minds behind Neo Elegance have designed the Lumineo professional device, their latest contribution to aesthetic treatment clinics and salons across the country that it has been excited to unveil. The launch went off with great success, and it has become known quickly as a device perfect for dermatologists, incorporating wavelengths that penetrate the skin and get to work with speed and effectiveness, only requiring a 10-minute treatment time. The slimline design gives it a sleek and elegant look that will be the pride of any professional skincare expert’s repertoire, and clients have loved the results it delivers thus far, whether alone or in conjunction with other treatments. Crucially, the draw of the Lumineo professional in that it accelerates wound healing, boosts collagen, evens out the skin tone of a client, and even reduces breakouts, being a pain free and thoroughly relaxing treatment that can reduce the downtime of more advanced aesthetic treatments. Neo Elegances’ professional quality LED products are now available for use at home, to help cleints maintain their skin in between professional treatments. They’ve helped so many users to reduce their problem skin like acne and improve anti-ageing routines with the power of LED Light. Neo Elegance plans to continue innovating with LED light technology and looks to introduce LED beds for full body treatments and more exciting innovations. Company: Neo Elegance Contact: Farrah Allarakha Website: Jul21624 The Bright Lights of Aesthetic Excellence

GHP / Q3 2021 15 , Jul21289 VativoRx is a full-service, innovative, leading solutions provider in Pharmacy Benefit Management (PBM) and rebate management services. More than a benefits processor, VativoRx designs andmanages cost-saving prescription benefit programmes that provide opportunities to optimise overall plan performance while maintaining superior pharmacy benefits to the planmembers. From formularymanagement to pharmacy networks, to costeffective clinical programmes, VativoRx will look at the client’s programme from every angle to helpmaximise pharmacy benefits for members while still controlling costs. Global Health & Pharmamagazine has recognised VativoRx as the Best Full-Service Pharmacy Benefit Management Solutions Provider 2021 – USA, so we take a closer look at what makes it an award-winning company. VativoRx’s message is simple: PBMs can do better. As an industry, it can do better at lowering costs. It can do better in being transparent. It can do better to ensure that the patient has the best possible access to prescription medicine while controlling pharmacy spend and not compromising care. Managing prescription benefits is complex and specialised business. Consumers may not have the expertise and knowledge to effectively navigate through the pharmacy benefit management landscape. VativoRx is uniquely positioned to guide its clients through the ever-changing complex healthcare marketplace to find cost saving solutions for both the client and the plan members. It utilises its proprietary software applications to develop a custom plan for each of its customers, which balances both cost savings and member sensitivity. VativoRx is showing by example that PBMs can do better. CEO, managing partner, and co-founder of VativoRx, Lisa Quarterman has been involved in the PBM industry for more than 20 years. She founded and owned Cypress Care, one of the largest workers’ compensation PBMs. Lisa grew Cypress Care from one person in her basement to 450 employees. She sold the business and decided to take a break to raise her kids. After four years in retirement, she realised there was a need and opportunity to make an impact in the PBM space by helping clients manage their pharmacy spend. Her path crossed with Michael Bogachek, who was already established in the pharmacy business. Together, they came up with the idea to start a new innovative PBM business that would utilise technology to help clients manage their drug spend, reduce costs, increase adherence rates, and at the same time provide exceptional patient care. Lisa decided it was time to come out of retirement and make her mark in the PBM business. In 2016, Lisa founded VativoRx, which has now grown to be one of the most successful rebate management PBMs. Lisa was most recently awarded 2020 Entrepreneur of the Year by Healthcare Tech Outlook Magazine while VativoRx was also recognised as one of the Top 10 Pharmacy Management Solution Providers of 2020 and 2021. Looking towards the future of the PBM industry, VativoRx expects intensive focus around rising drug costs, non-adherence, and patient affordability. Everybody talks about the need for affordable healthcare, but when it comes down to it, the vast majority of the cost is borne by plan sponsors – the companies offering their members health benefits and the members themselves. VativoRx focuses on making that cost as low as possible while still delivering robust pharmacy benefits and outstanding service. Technology allows VativoRx to provide services at a minimal cost because its infrastructure and operations run so efficiently. This allows it to be very nimble and flexible while providing exceptional service. It is building software that’s integrating its company, its customers, and the healthcare providers altogether. The company plans to eventually build the pharmacy management with the total healthcare of a patient and give the healthcare providers the foresight into how the pharmacy prescriptions are affecting the total care of a patient. VativoRx offers what the large PBMs offer at a more affordable price, with transparency, and with proven results. VativoRx blends innovative technology with sound business strategies to deliver process enhancements and real healthcare savings. Its holistic approach to managing the healthcare spend, including customised utilisation management programmes that align with its clients’ interests, aggressive rebate management solutions, real-time access to claims detail and reporting, and flexible transparent pricing, makes for a better full-service PBM. Contact: Lisa Quarterman Email: [email protected] Website: PBMs Can Do Better

16 GHP / Q3 2021 , Jul21208 Based in Crawley, West Sussex, Crawley Chiropractic Centre aims to offer its clients a variety of treatment options tailored to help themachieve the health and wellbeing they desire. We profiled the clinic to find out more about how it works with clients to ensure they get the most out of their care. Supporting clients of all ages and abilities, Crawley Chiropractic Centre treats a range of ailments including neck, back and shoulder pain. The Centre also offers innovative treatments for headaches, sciatica and stress management. Dr Danny Scahill DC (Doctor of Chiropractic) is the founder of Crawley Chiropractic Centre, the author of the book “Total Health Transformation – The Proven System to Unlock Limitless Energy, Motivation and Health” and the creator of the Total Health Transformation Programmes. Dr Danny has been in practice since 2006. In that time he has helped thousands of clients in the UK and Ireland. Dr Danny graduated from The Welsh Institute of Chiropractic (WIOC) in Glamorgan, South Wales obtaining a BSc (Hons) Chiropractic degree in 2006. He completed the five-year Bachelor of Science degree in Chiropractic after previously completing 4 years study of Osteopathy. Dr Danny has worked in busy multi doctor Chiropractic practices in Dublin, Ireland for 4 years and has been a Chiropractor in Crawley for the last 11 years. During this time he has acquired an excellent reputation for being a Chiropractor who listens and cares for his clients, and as such everyone who visits Crawley Chiropractic Clinic of the Year 2021 - Sussex Chiropractic Centre knows they are in safe hands. With a team of friendly and approachable staff behind him, Dr Danny is able to welcome everyone - from adults through to children - to Crawley Chiropractic Centre. The team work with clients throughout the lifetime of their care to ensure that they get optimal results. They know that communication is key and run regular workshops to give people the information they need to make the best possible health choices and achieve all their health goals. Seeking to build upon their reputation for excellence, Crawley Chiropractic Centre will continue to welcome a range of new clients and provide them with the award-winning care and support that they deserve and come to expect. Company: Crawley Chiropractic Centre Tel: 01293 511265 Contact: Dr Danny Scahill DC Website:

GHP / Q3 2021 17 , Jun21728 Care That is Truly Unrivalled Established by Nichola Overington in 2013, Overington Care Ltd is an independent awardwinning dedicated care service which supports clients in living their lives the way they want to. The agency has achieved the title of Best Elderly and Adult Home Care Services Provider 2021 – SouthWest UK in recognition of it bringing joy to the local community with its wide range of care services which assist people to live happily with dignity and independence. Situated in the delightful seaside town of Seaton in Devon, Overington Care’s main priority is its clients’ personal fulfilment. It believes that everyone should have the opportunity to maintain their independence and to remain in the privacy and comfort of their own home, so its services assist people at home on a one-to-one basis. It considers its clients as an equal partner in making decisions about the level of care and support they receive, with the service being tailored to their individual needs. Services that can be provided include assistance with getting up in the morning and going to bed; all personal care, including washing, bathing, etc.; assisting with dressing and undressing; preparing, cooking and serving meals; housework and cleaning tasks; washing of laundry and ironing; companionship at home or for social activities; escorts to appointments; end of life care at home; and more. There are extra services available which include trips to the hairdressers; trips out shopping to the individual’s destinations of choice; afternoon tea at various locations along the Jurassic Coast; trips to see friends and family members; trips to the theatre; assisted afternoon walks along the seafront (weather permitting); and carer/ companion for short holiday breaks (maximum of two weeks). Overington Care founder, Nichola Overington has over 28 years of experience in the health and social care sector and she truly cares about each and every patient she works with. Overington Care was born when she decided that there was an opportunity to create a service which rivalled existing care agencies by offering a higher standard of care. In the time that the care agency has been in business, it has gained an excellent reputation in the community for reliably supplying outstanding care. In addition to providing daily care for clients, Overington Care has this June introduced The HUB, a locally registered charity which provides a vibrant social centre for the community. It provides refreshments and homemade cakes; daily social inclusion activities, both engaging and educational, which include sensory sessions, flower arranging/herb potting, knitting and crochet, music/singing and guest musicians, animal therapy, quizzes and board games, arts and crafts, movies, chair exercises/yoga, and more; social outings using The HUB minibus; treatment/spa room which is bookable upon request for a hair wash or blow dry, or an indulging foot spa; informative talks and support groups; training; and much more! There is also a small retail unit by Overington Care, a conference room, and technology facilities. As we get older, life can become very isolated and lonely. Isolation and loneliness can lead to silence and boredom, making very long days which lack fun and laughter, and this can naturally have a detrimental effect on mental and physical health. This is why Overington Care wanted to create The HUB, a safe place of interests and activities, which can bring individuals out of isolation and back into the community. A place where everyone can come together, live life, socialise with one another, and have a reason to get up every day and look forward to the day that lies ahead. Indeed, Overington Care’s staff go above and beyond to lift the spirits of the local community. They are passionate, dedicated and driven, and this is enhanced by the weekly training sessions provided by The Royal Devon and Exeter Hospital, led by hospital nurses on topics such as pressure sore prevention, dysphasia, oral care, and lots more. This extra knowledge gained by Overington Care’s staff can help reduce the pressure on the District Nursing team and any unnecessary admissions. Overington Care ultimately supports its staff to aim as high as they would like in terms of achieving further qualification and it couldn’t be prouder of each and every one of them. Contact: Nichola Overington Email: [email protected] Website:

18 GHP / Q3 2021 , Accredited as the ‘Best for Innovative Facial Sculpting Treatments’ for 2021, Facial Sculpting is the non-surgical aesthetic treatment company causing a stir with its myriad of exemplary new treatments. Most recently, these have been joined by Profhilo and Endolift, separate elements of a 2-part treatment that combines injection and laser therapy in order to give results that are visible in amatter of weeks. Facial Sculpting is an aesthetic medical technologies innovator leading the charge in nonsurgical aesthetic procedures, led by expert doctor and influential voice in her field, Dr Nina Bal. Recently, its exemplary new facelift technologies have been causing a stir amongst her peers as she continues to develop new and exemplary treatments. A combined treatment with two separate parts – Profholio and Endolift – it has quickly earned the top spot for the best non-surgical facelift option in the market for the near instant results that it allows patients to see mere weeks after the treatment. Dr Nina guarantees that patients will be seeing results within three to six weeks of their appointment. Fundamentally, this is some of this quickest recovery and visible results turnaround available on the market right now, with said results lasting up to two years without further aid or intervention from the team at Facial Sculpting. The treatments, in essence, work well together because Profhilo treats the skin’s laxity, improving the firmness of the dermal layer and targeting that part of the skin in particular, whilst Endolift goes deeper, tightening the skin layer The New Non-Surgical Aesthetic Treatment from Nina Bal underneath the subcutaneous layer in order to give the best non-surgical face lift that a client could find. ‘It truly works wonders’, Dr Nina tells us, going a little deeper into the procedure itself to explain the time frames; one way it can be done is by giving a client their first session of Profhilo, 4 weeks after which their first Endolift session will take place, with the second Profhilo session being done in tandem with it. The other available timeframe is an Endolift treatment and first session of Profhilo together, with the second session of Profhilo four weeks later. Moreover, it hastens to add that this facelift option moisturises as well as tightens as it works beneath the skin, using pure hyaluronic acid in its work, resulting in a truly revolutionary facelift solution that remodels aging and sagging skin tissue for the face, neck, décolletage, hands, arms, knees, and abdomen. It also rejuvenates, stimulating the production of collagen, plumping skin in order to reduce the appearance of lines and wrinkles and give a natural looking youthful countenance. Endolift, in addition, is a combined laser application that combines rejuvenation and facial contouring, meaning a client can achieve the same results of surgery without ever having to go under the knife, granting them peace of mind – they can also rest assured that Dr Nina’s team will only ever use the best equipment and procedures. Client safety and comfort is the core priority for herself and her team. The Endolift laser treatment is performed by way of the latest Eufoton LASmar 1500 – certified by the American FDA – and under local anaesthetic that results in minimal swelling, allowing clients to return to their everyday life in the same day. Dr Nina, a Diamond Awards 2021 Finalist, Private Health Awards winner, Global Excellence Awards 2020 winner, Facial Aesthetics finalist, and member of the best young dentist shortlist, looks forward to plying this treatment for many more clients in the future as Facial Sculpting continues to lead the way in UK aesthetic treatments. Company: Facial Sculpting Contact: Nina Bal Website: https://www. Jun21581

GHP / Q3 2021 19 , Comprehensive Compliance Solutions for Medical Technology Pharmalex GmbH is a company that has been growing naturalistically and on a global scale, providing regulatory compliance for amyriad of diverse clients across the industries of pharmaceutical product development, biotech, andmedical devices. It is this work that has earned it the ‘Best Medical Device Development and Regulatory Strategy Company’ award for the USA in 2021, and we touched base with the company itself to find out just what about it has earned it somuch trust. Supporting the pharmaceutical, biotechnology, and medical device sectors of its industry, Pharmalex ensures that the companies in these categories are serving their market segments with compliant and safe products throughout every stage of their product lifecycle. Fundamentally, its services entail the quality and regulatory support of clinical and non-clinical development, as well as market authorisations, post market activities, and medical affairs, supporting companies to make sure that each detail is seen to throughout their journey to greater success. Furthermore, this follows its ethos of providing flexible, costeffective solutions for all budding medical technology companies, enabling new products and innovations to be brought to the market. This will be increasingly invaluable as the medical sector continues to adapt and change in the face of the post-Covid19 worldwide paradigm, enabling the development, manufacture, and quality assurance of diagnostic, treatment, and patient wellbeing focused technologies at an improved rate. It also helps its clients to be confident about the products they have developed. By following their motto at every step of the development process, it strives to help its clientele meet and exceed regulatory compliance standards in order to make their products the cutting edge of the latest and greatest, in order to help medical technologies meet, maintain and exceed compliance requirements, capitalizing on greater efficiency and less complexity through its regulatory lifecycle. Additionally, in order to do this, Pharmalex has ensured that its growth has taken place upon a few keystone pillars: its work promises to be flexible; and it delivers subject matter experts and tailored solutions that will always be exactly relevant to what a client wishes to bring to the table. In this manner, part of Pharmalex core is using Technology Enabled Solutions to ensure that it has the innovative solution needed to help a company manage risks and optimize their processes across the board, allowing the products they have developed to quickly prove the competence and reliability of the work behind them from the testing to the market value. It is also driven by a passion for its work. Its team thrives on navigating complex regulatory environments, and its efficiency and dedication in doing so has been widely lauded as exemplary. Essentially, each of these principles allow Pharmalex to provide expert, first-class, intelligent solutions that focus in on supporting a client through tactical support, preferred provider models, and strategic collaborative partner models, derived from its commitment to its core values and made possible by its 1,700 employees across 45 offices. In addition, its experts are capable of handling the entire continuum of regulatory needs for medical devices, IVDs and diagnostic technologies, and Pharmalex thanks each and every one of them for their continued commitment to the client and the industry. In return, Pharmalex supports its colleagues with the maintenance of a global support network, allowing them to communicate with people across a range of disciplines. The result of this is a staff with many exciting avenues available when it comes to their professional development, and Pharmalex finds it an incredibly important aspect of its business model that its staff are as well looked after as its clients, ensuring the continued success of the company as a whole. Lastly, with business having increased over the past year, Pharmalex plans to continue using its current growth spurt as a springboard to further development, maintaining its current projects and pushing on with its virtual support and remote work. Company: Pharmalex GmbH Website: Email: [email protected]